Risk of recurrent venous thromboembolism (VTE) after stopping anticoagulant therapy.
Variable . | Relative Risk . |
---|---|
For supporting references, see text and Kearon5 | |
Abbreviations: DVT, deep venous thrombosis; PE, pulmonary embolism | |
Transient risk factor | ≤ 0.5 |
Persistent risk factor | ≥ 2 |
Unprovoked VTE | ≥ 2 |
Protein C, protein S and antithrombin deficiency | 1–3 |
Heterozygous for factor V Leiden | 1–2 |
Homozygous for factor V Leiden | 4.1 |
Heterozygous for G20210A mutation in the prothrombin gene | 1–2 |
Heterozygous for both factor V Leiden and G20210A prothrombin gene | 2–5 |
Factor VIII level > 200 IU/dL | ~6 |
Antiphospholipid antibodies | 2–4 |
Mild hyperhomocysteinemia | 2.7 |
D-dimer elevation after stopping therapy | ~2 |
Family history of VTE | ~1 |
Cancer: | ~3 |
Metastatic vs non-metastatic | ~3 |
Chemotherapy | ~2 |
Discontinuation of estrogen | < 1 |
Proximal DVT versus PE | ~1 |
Distal DVT versus proximal DVT or PE | 0.5 |
Residual thrombosis | 1–2 |
Vena caval filter | ~1.8 |
Second versus first episode of VTE | ~1.5 |
Age at diagnosis of VTE | ≥1 |
Male gender | ~1.5 |
Asian | ~0.8 |
Variable . | Relative Risk . |
---|---|
For supporting references, see text and Kearon5 | |
Abbreviations: DVT, deep venous thrombosis; PE, pulmonary embolism | |
Transient risk factor | ≤ 0.5 |
Persistent risk factor | ≥ 2 |
Unprovoked VTE | ≥ 2 |
Protein C, protein S and antithrombin deficiency | 1–3 |
Heterozygous for factor V Leiden | 1–2 |
Homozygous for factor V Leiden | 4.1 |
Heterozygous for G20210A mutation in the prothrombin gene | 1–2 |
Heterozygous for both factor V Leiden and G20210A prothrombin gene | 2–5 |
Factor VIII level > 200 IU/dL | ~6 |
Antiphospholipid antibodies | 2–4 |
Mild hyperhomocysteinemia | 2.7 |
D-dimer elevation after stopping therapy | ~2 |
Family history of VTE | ~1 |
Cancer: | ~3 |
Metastatic vs non-metastatic | ~3 |
Chemotherapy | ~2 |
Discontinuation of estrogen | < 1 |
Proximal DVT versus PE | ~1 |
Distal DVT versus proximal DVT or PE | 0.5 |
Residual thrombosis | 1–2 |
Vena caval filter | ~1.8 |
Second versus first episode of VTE | ~1.5 |
Age at diagnosis of VTE | ≥1 |
Male gender | ~1.5 |
Asian | ~0.8 |